Q-omics provides the consensus-scored AKAP6 profile across patient tissues and cancer cell-line models. AKAP6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKAP6 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, AKAP6 RNA expression shows 19,952 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where AKAP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKAP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKAP6 survival associations across molecular data types. AKAP6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKAP6 RNA expression–survival associations across cancer types. High AKAP6 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, ACC, LGG, KIRP and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKAP6 RNA expression.
This table summarizes AKAP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for AKAP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKAP6 shows lower tumor expression in BLCA, THCA, COAD, LUSC, BRCA and HNSC. The BLCA box plot shows higher AKAP6 RNA expression in normal versus tumor tissue (log2 FC = −2.905, t-test p < 0.001).
This table shows molecular features associated with AKAP6 in patient tissues and cancer cell lines. In patient samples, AKAP6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AKAP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
